OLIGONUCLEOTIDE THERAPEUTICS SOCIETY INC

What OLIGONUCLEOTIDE THERAPEUTICS SOCIETY INC does

The Oligonucleotide Therapeutics Society (OTS) is a nonprofit professional society headquartered in San Diego, California, founded to serve as an open forum uniting academia, industry, and government around the research and development of oligonucleotide therapeutics. The society operates a portfolio of community-building programs rather than a single product: an Annual Meeting (the 22nd scheduled for October 11–14, 2026 in Denver, CO), a recurring OTS Webinar series, an Educational Video Library hosted on YouTube, a Mentorship Program, a Rare Disease Task Force, an OTS Journal, and an awards and grants program (Lifetime Achievement, Fritz Eckstein Mid-Career Achievement, Young Investigator, Alan M. Gewirtz Memorial Scholarships, Paper of the Year, Poster Awards, Local & Regional Delivery Grants, Travel Grants). It also operates a free Job Board for the oligonucleotide field.

OTS generates revenue through three streams: recurring membership dues, one-time event registrations for the annual meeting, and corporate sponsorships drawn from oligonucleotide developers and life-sciences suppliers (Ionis Pharmaceuticals as Platinum sponsor; Alnylam, Arrowhead, Roche, Sarepta, Thermo Fisher, ChemGenes, and Dicerna as Annual Meeting sponsors). Specific pricing is not publicly disclosed. The society is governed by a Board of Directors and Scientific Advisory Council, led by President Rebecca Miles, PhD, with a 1–10 employee operational footprint, and serves a global membership across the USA, UK, France, and broader Europe. There are no funding rounds, no M&A activity, no patents, and no proprietary technology products — OTS's "platform" is its convening power, content library, and community ecosystem.

Name

OLIGONUCLEOTIDE THERAPEUTICS SOCIETY INC

Legal name

Oligonucleotide Therapeutics Society

Website

https://oligotherapeutics.org

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

The Oligonucleotide Therapeutics Society is a San Diego-based nonprofit scientific society that convenes academia, industry, and government through annual meetings, webinars, awards, a journal, a job board, and mentorship programs to advance oligonucleotide therapeutics research and development globally.

Ownership category

akta.pro rank

Product category

Life Sciences Professional Society

NAICS

Voluntary Health Organizations (813212), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Scientific society membership
• Oligonucleotide therapeutics research
• Annual scientific conferences
• Professional development webinars
• Life sciences community

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Dues: OTS generates revenue through membership fees that provide access to an array of benefits supporting the society's mission to foster academia and industry-based research and development of oligonucleotide therapeutics.
2. Event Registrations: The society generates revenue through annual meeting registrations, with the 22nd Annual Meeting scheduled for October 2026 in Denver, CO, and past meetings in 2021-2025.
3. Sponsorships: Pharmaceutical and life sciences companies sponsor annual meetings and events, including Platinum Sponsors such as Ionis Pharmaceuticals and others in the oligonucleotide therapeutics industry.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Oligonucleotide Therapeutics Society Inc is a nonprofit professional scientific society that operates as an open forum to foster research and development of oligonucleotide therapeutics. It delivers value through paid membership programs, an annual scientific conference, an educational webinar series, a peer-reviewed journal, a job board, an awards and grants program, a mentorship program, and a rare disease task force that brings together academia, industry, and government scientists worldwide.

Product overview

The Oligonucleotide Therapeutics Society (OTS) is a professional society rather than a product company. It operates as an open, nonprofit forum to foster research and development of oligonucleotide therapeutics. The society provides a platform of interconnected programs and services including Annual Meetings for knowledge sharing among scientists and industry leaders, Webinars for ongoing education, Awards & Grants to support researchers at various career stages, a Job Board connecting employers with talent in the field, Science News & Publications including a journal and educational materials, a Mentorship Program for professional development, and a Rare Disease Task Force focused on oligonucleotide approaches for ultra-rare diseases. These offerings work together to unite experts across academia, industry, and government to advance oligonucleotide therapeutics through community, collaboration, innovation, and education.

Differentiator

Problem solved

Functional benefit

Products and services

• OTS Annual Meetings Recurring in-person scientific conference bringing together top scientists, innovators, and industry leaders in oligonucleotide research, with over 1,000 attendees and 100+ posters at recent meetings.
• OTS Membership Recurring paid membership providing access to the society's journal, educational content, networking, awards eligibility, and member benefits for researchers and industry professionals.
• OTS Webinars

Quantifiable outcome

• Over 100 oligonucleotide treatments in development for various diseases
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

13 partnerships are on record, tiered core and minor.

• Ionis PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2021Ionis Pharmaceuticals is a Platinum Sponsor of the OTS Annual Meeting. As a major pharmaceutical company in the oligonucleotide therapeutics space, Ionis supports the society's mission to advance oligonucleotide research and development through event sponsorship and collaboration.
• Alnylam PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2021Alnylam Pharmaceuticals is an Annual Meeting Sponsor supporting OTS events. Alnylam is a leading RNAi therapeutics company that sponsors the society's activities to foster collaboration in the field.
• Arrowhead PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2021Arrowhead Pharmaceuticals sponsors OTS Annual Meetings. The company develops RNA interference therapeutics and supports the society's educational and networking initiatives.
• RochecoreStrategic or Co-development Partner · 1 January 2021Roche is an Annual Meeting Sponsor of OTS. As a major pharmaceutical company engaged in oligonucleotide therapeutics research, Roche supports the society's mission.
• Sarepta TherapeuticscoreStrategic or Co-development Partner · 1 January 2021Sarepta Therapeutics sponsors OTS Annual Meetings. The company focuses on precision genetic medicine and supports the society's collaborative efforts.
• Dyne TherapeuticsminorStrategic or Co-development Partner · 1 January 2021Dyne Therapeutics is an Annual Meeting Sponsor. The company develops DNA therapeutics for muscle disease and supports OTS programming.
• Olix PharmaceuticalsminorStrategic or Co-development Partner · 1 January 2021Olix Pharmaceuticals sponsors OTS Annual Meetings. The company develops RNA-based therapeutics and supports the society's mission.
• Aligos TherapeuticsminorStrategic or Co-development Partner · 1 January 2021Aligos Therapeutics is an Annual Meeting Sponsor supporting OTS activities in the oligonucleotide therapeutics field.
• ChemGenescoreStrategic or Co-development Partner · 1 January 2021ChemGenes is an Annual Meeting Sponsor providing oligonucleotide synthesis reagents and supporting OTS educational initiatives.
• AxolabsminorStrategic or Co-development Partner · 1 January 2021Axolabs sponsors OTS Annual Meetings. The company provides drug delivery solutions for oligonucleotides.
• Thermo Fisher ScientificcoreStrategic or Co-development Partner · 1 January 2021Thermo Fisher Scientific is an Annual Meeting Sponsor. As a major life sciences supplier, they support the society's activities and benefit from visibility among oligonucleotide researchers.
• Dicerna PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2021Dicerna Pharmaceuticals sponsors OTS Annual Meetings. The company develops RNA interference therapeutics using its proprietary GalXC technology.
• DuPont Technology (formerly DuTeX)minorStrategic or Co-development Partner · 1 January 2021DuPont Technology (formerly DuTeX) sponsors OTS Annual Meetings. The company provides oligonucleotide synthesis solutions.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Drug Information Association (DIA): DIA is a neutral, member-driven professional association for the life sciences industry covering drug development and regulatory science. It competes for sponsorship and meeting attendance from the same pharma/biotech audience OTS serves, though DIA's scope is far broader.
• American Association of Pharmaceutical Scientists (AAPS): AAPS is a professional society of pharmaceutical scientists with annual meetings, journals, and awards. It overlaps with OTS in serving pharmaceutical scientists working on drug delivery and development, including oligonucleotide delivery, but at a broader pharmaceutical-sciences level.
• Biotechnology Innovation Organization (BIO): BIO is the largest biotech trade association, representing the broader biopharmaceutical industry including oligonucleotide developers. It is a much larger incumbent society that overlaps with OTS's industry-academia mission but at a portfolio-wide level rather than the oligo-specific niche.
• American Chemical Society (ACS) - Division of Medicinal Chemistry: ACS's Medicinal Chemistry Division serves chemists designing nucleic-acid-based drugs and holds sessions overlapping with oligonucleotide therapeutics. It is a broad incumbent society whose members include many of the same medicinal chemists attending OTS meetings.

Direct peers

• The RNA Society: The RNA Society is a nonprofit scientific society dedicated to RNA research broadly, with an annual meeting, journal (RNA), and awards. It serves overlapping academic constituencies and operates the same kind of membership-driven forum model as OTS, but with broader RNA biology scope rather than therapeutics focus.
• Gordon Research Conferences: Gordon Research Conferences runs nonprofit, invitation-style scientific conferences on cutting-edge topics including nucleic acids and RNA. It is a structural peer to OTS in running high-quality, focused scientific meetings for the research community.
• Keystone Symposia: Keystone Symposia runs topic-focused scientific conferences (including on RNA biology and gene therapy) in a nonprofit model. It is directly comparable to OTS in organizing niche scientific conferences and is a structural peer for OTS's annual meeting format.
• International Society for Cell & Gene Therapy (ISCT): ISCT is a global scientific society driving the translation of cell and gene therapies. It operates with a similar nonprofit professional society model, annual meetings, working groups, and a journal — directly comparable in mission and structure to OTS in the adjacent cell/gene therapy space.
• American Society of Gene & Cell Therapy (ASGCT): ASGCT is the largest nonprofit scientific society focused on gene and cell therapy, with overlapping membership in nucleic-acid therapeutics and similar programming (annual meeting, journal Molecular Therapy, awards). It is the closest direct peer in mission, structure, and member demographics to OTS.

Regional players

• European Association for Cancer Research (EACR): EACR is a European nonprofit membership society for cancer researchers. While primarily regional (Europe) and broader in scope (cancer), it has overlapping academic constituencies and similar operating model to OTS, and OTS already lists France and the UK as operating geographies.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCLIsR9QwHrTIrc105-0QdIQ/videos
• Xx.com/otsociety
• Facebookfacebook.com/oligotherapeutics
• LinkedInlinkedin.com/company/oligotherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OLIGONUCLEOTIDE THERAPEUTICS SOCIETY INC